CME Group (CME) Stock Forecast, Price Target & Predictions
CME Stock Forecast
CME Group stock forecast is as follows: an average price target of $213.88 (represents a -1.43% downside from CME’s last price of $216.99) and a rating consensus of 'Buy', based on 13 wall street analysts offering a 1-year stock forecast.
CME Price Target
The average price target for CME Group (CME) is $213.88 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $280.00 to $151.00. This represents a potential -1.43% downside from CME's last price of $216.99.
CME Analyst Ratings
According to 13 Wall Street analysts, CME Group's rating consensus is 'Buy'. The analyst rating breakdown for CME stock is 0 'Strong Buy' (0.00%), 6 'Buy' (46.15%), 6 'Hold' (46.15%), 1 'Sell' (7.69%), and 0 'Strong Sell' (0.00%).
CME Group Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 03, 2024 | Craig Siegenthaler | Bank of America Securities | $177.00 | $215.74 | -17.96% | -18.43% |
| Jul 25, 2024 | Brian Bedell | Deutsche Bank | $193.00 | $198.92 | -2.98% | -11.06% |
| Jul 25, 2024 | Patrick Moley | Piper Sandler | $225.00 | $199.38 | 12.85% | 3.69% |
| Jul 25, 2024 | Benjamin Budish | Barclays | $209.00 | $197.25 | 5.96% | -3.68% |
| Jun 05, 2024 | Alex Kromm | UBS | $250.00 | $203.78 | 22.68% | 15.21% |
| Apr 25, 2024 | Andrew Bond | Rosenblatt Securities | $187.00 | $212.59 | -12.04% | -13.82% |
| Apr 25, 2024 | Benjamin Budish | Barclays | $228.00 | $212.59 | 7.25% | 5.07% |
| Apr 05, 2024 | Brian Bedell | Deutsche Bank | $210.00 | $212.21 | -1.04% | -3.22% |
| Feb 07, 2023 | - | Credit Suisse | $198.00 | $174.76 | 13.30% | -8.75% |
| Jan 11, 2023 | - | Morgan Stanley | $196.00 | $176.93 | 10.78% | -9.67% |
The latest CME Group stock forecast, released on Sep 03, 2024 by Craig Siegenthaler from Bank of America Securities, set a price target of $177.00, which represents a -17.96% decrease from the stock price at the time of the forecast ($215.74), and a -18.43% decrease from CME last price ($216.99).
CME Group Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 4 | 8 |
| Avg Price Target | $177.00 | $201.00 | $209.88 |
| Last Closing Price | $216.99 | $216.99 | $216.99 |
| Upside/Downside | -18.43% | -7.37% | -3.28% |
In the current month, the average price target of CME Group stock is $177.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a -18.43% decrease as opposed to CME Group's last price of $216.99. This month's average price target is down -11.94% compared to last quarter, and down -15.67% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 05, 2024 | Citigroup | Buy | Buy | Hold |
| Sep 03, 2024 | Bank of America Securities | Neutral | Underperform | Downgrade |
| Aug 15, 2024 | Sandler O'Neill | Market Perform | Market Perform | Hold |
| Aug 15, 2024 | Sandler O'Neil | Underperform | Underperform | Hold |
| Jul 25, 2024 | Deutsche Bank | Hold | Hold | Hold |
| Jul 25, 2024 | Sandler O'Neill | Market Perform | Market Perform | Hold |
| Jul 25, 2024 | Sandler O'Neil | Underperform | Underperform | Hold |
| Jul 25, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 25, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jul 09, 2024 | Piper Sandler | Market Perform | Market Perform | Hold |
CME Group's last stock rating was published by Citigroup on Sep 05, 2024. The company gave CME a "Buy" rating, the same as its previous rate.
CME Group Financial Forecast
CME Group Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $1.44B | $1.34B | $1.36B | $1.44B | $1.21B | $1.23B | - | $1.35B | $1.15B | $1.11B | $1.18B | $1.25B | $1.10B | $1.08B | $1.18B | $1.52B | $1.14B | $1.28B |
| Avg Forecast | $1.62B | $1.63B | $1.67B | $1.64B | $1.55B | $1.52B | $1.55B | $1.54B | $1.50B | $1.51B | $1.53B | $1.48B | $1.43B | $1.34B | $1.34B | $1.41B | $1.21B | $1.22B | $1.25B | $1.33B | $1.17B | $1.15B | $1.17B | $1.26B | $1.10B | $1.09B | $1.19B | $1.49B | $1.15B | $1.27B |
| High Forecast | $1.71B | $1.72B | $1.77B | $1.73B | $1.64B | $1.61B | $1.64B | $1.62B | $1.58B | $1.61B | $1.62B | $1.56B | $1.44B | $1.36B | $1.42B | $1.49B | $1.28B | $1.29B | $1.25B | $1.39B | $1.22B | $1.20B | $1.23B | $1.32B | $1.15B | $1.15B | $1.25B | $1.56B | $1.20B | $1.33B |
| Low Forecast | $1.53B | $1.54B | $1.58B | $1.55B | $1.47B | $1.44B | $1.47B | $1.45B | $1.42B | $1.44B | $1.45B | $1.40B | $1.41B | $1.33B | $1.27B | $1.34B | $1.15B | $1.15B | $1.25B | $1.25B | $1.10B | $1.08B | $1.11B | $1.19B | $1.04B | $1.03B | $1.13B | $1.41B | $1.09B | $1.20B |
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 7 | 7 | 8 | 7 | 10 | 9 | 6 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.00% | 1.01% | 1.02% | 1.00% | 1.01% | - | 1.02% | 0.98% | 0.97% | 1.01% | 0.99% | 1.00% | 0.99% | 0.99% | 1.02% | 0.99% | 1.01% |
CME Group's average Quarter revenue forecast for Mar 24 based on 4 analysts is $1.48B, with a low forecast of $1.40B, and a high forecast of $1.56B. CME's average Quarter revenue forecast represents a 2.56% increase compared to the company's last Quarter revenue of $1.44B (Dec 23).
CME Group EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 7 | 7 | 8 | 7 | 10 | 9 | 6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $949.50M | $-170.30M | $-422.30M | $1.00B | $745.70M | $828.80M | - | $951.00M | $867.90M | $1.09B | $801.90M | $861.10M | $666.10M | $672.60M | $784.40M | $1.05B | $634.60M | $714.90M |
| Avg Forecast | $985.12M | $990.83M | $1.02B | $996.47M | $942.55M | $926.54M | $944.58M | $933.35M | $911.55M | $917.54M | $931.67M | $1.20B | $867.83M | $815.24M | $814.47M | $1.09B | $735.92M | $741.92M | $756.86M | $992.91M | $924.29M | $695.91M | $836.83M | $871.22M | $686.23M | $711.22M | $811.46M | $1.09B | $792.86M | $816.63M |
| High Forecast | $1.04B | $1.05B | $1.07B | $1.05B | $995.03M | $978.12M | $997.18M | $985.32M | $962.31M | $979.12M | $983.54M | $1.44B | $873.90M | $823.40M | $859.82M | $1.31B | $776.89M | $783.23M | $756.86M | $1.19B | $1.11B | $728.71M | $1.00B | $1.05B | $823.48M | $853.46M | $973.75M | $1.31B | $951.44M | $979.95M |
| Low Forecast | $931.56M | $936.96M | $961.23M | $942.30M | $891.31M | $876.17M | $893.23M | $882.61M | $862.00M | $874.43M | $881.02M | $961.14M | $855.69M | $806.87M | $770.19M | $873.76M | $695.91M | $701.59M | $756.86M | $794.33M | $739.43M | $657.39M | $669.46M | $696.98M | $548.99M | $568.97M | $649.17M | $872.78M | $634.29M | $653.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.09% | -0.21% | -0.52% | 0.92% | 1.01% | 1.12% | - | 0.96% | 0.94% | 1.56% | 0.96% | 0.99% | 0.97% | 0.95% | 0.97% | 0.96% | 0.80% | 0.88% |
4 analysts predict CME's average Quarter EBITDA for Mar 24 to be $1.20B, with a high of $1.44B and a low of $961.14M. This is 26.53% upper than CME Group's previous annual EBITDA (Dec 23) of $949.50M.
CME Group Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 7 | 7 | 8 | 7 | 10 | 9 | 6 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $804.30M | $750.20M | $777.60M | $883.80M | $637.90M | $679.60M | - | $711.00M | $625.20M | $926.50M | $510.30M | $574.40M | $424.00M | $411.70M | $503.30M | $766.20M | $469.50M | $636.30M |
| Avg Forecast | $909.62M | $930.21M | $964.83M | $959.27M | $878.52M | $882.82M | $908.29M | $905.54M | $860.72M | $893.98M | $911.63M | $812.99M | $821.43M | $799.89M | $792.06M | $739.08M | $677.15M | $993.02M | $696.08M | $671.89M | $617.58M | $902.74M | $494.25M | $561.27M | $417.81M | $420.46M | $500.19M | $731.84M | $475.60M | $585.69M |
| High Forecast | $975.46M | $997.54M | $1.03B | $1.03B | $942.11M | $946.71M | $974.03M | $971.08M | $923.02M | $958.86M | $977.62M | $975.59M | $843.14M | $817.91M | $849.39M | $886.90M | $726.17M | $1.19B | $696.08M | $806.27M | $741.09M | $1.08B | $593.10M | $673.53M | $501.37M | $504.55M | $600.23M | $878.21M | $570.72M | $702.82M |
| Low Forecast | $845.34M | $864.47M | $896.64M | $891.48M | $816.43M | $820.43M | $844.10M | $841.54M | $799.89M | $847.12M | $847.20M | $650.39M | $806.96M | $785.48M | $736.08M | $591.27M | $629.30M | $794.41M | $696.08M | $537.52M | $494.06M | $722.19M | $395.40M | $449.02M | $334.25M | $336.37M | $400.15M | $585.47M | $380.48M | $468.55M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | 0.94% | 0.98% | 1.20% | 0.94% | 0.68% | - | 1.06% | 1.01% | 1.03% | 1.03% | 1.02% | 1.01% | 0.98% | 1.01% | 1.05% | 0.99% | 1.09% |
CME Group's average Quarter net income forecast for Mar 24 is $812.99M, with a range of $650.39M to $975.59M. CME's average Quarter net income forecast represents a 1.08% increase compared to the company's last Quarter net income of $804.30M (Dec 23).
CME Group SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 7 | 7 | 8 | 7 | 10 | 9 | 6 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $32.20M | $37.80M | $38.30M | $38.50M | $35.10M | - | $31.80M | $138.50M | $152.10M | $140.30M | $150.30M | $161.50M | $154.20M | $155.70M | $354.70M | $347.80M | $368.60M |
| Avg Forecast | $52.06M | $52.36M | $53.72M | $52.66M | $49.81M | $48.96M | $49.92M | $49.32M | $48.17M | $48.49M | $49.23M | $181.35M | $45.86M | $43.08M | $43.04M | $164.86M | $38.89M | $163.02M | $40.00M | $149.88M | $136.81M | $148.20M | $135.89M | $146.86M | $159.14M | $157.48M | $154.74M | $338.79M | $352.32M | $339.28M |
| High Forecast | $54.96M | $55.28M | $56.71M | $55.59M | $52.58M | $51.69M | $52.70M | $52.07M | $50.85M | $51.74M | $51.98M | $217.62M | $46.18M | $43.51M | $45.44M | $197.84M | $41.06M | $195.62M | $40.00M | $179.85M | $164.17M | $177.84M | $163.07M | $176.24M | $190.97M | $188.98M | $185.69M | $406.55M | $422.78M | $407.14M |
| Low Forecast | $49.23M | $49.51M | $50.80M | $49.80M | $47.10M | $46.30M | $47.20M | $46.64M | $45.55M | $46.21M | $46.56M | $145.08M | $45.22M | $42.64M | $40.70M | $131.89M | $36.78M | $130.42M | $40.00M | $119.90M | $109.45M | $118.56M | $108.71M | $117.49M | $127.31M | $125.98M | $123.79M | $271.04M | $281.85M | $271.42M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.75% | 0.88% | 0.23% | 0.99% | 0.22% | - | 0.21% | 1.01% | 1.03% | 1.03% | 1.02% | 1.01% | 0.98% | 1.01% | 1.05% | 0.99% | 1.09% |
CME Group's average Quarter SG&A projection for Dec 23 is $45.86M, based on 8 Wall Street analysts, with a range of $45.22M to $46.18M. The forecast indicates a 42.42% rise compared to CME last annual SG&A of $32.20M (Sep 23).
CME Group EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 7 | 7 | 8 | 7 | 10 | 9 | 6 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $2.24 | $2.06 | $2.14 | $2.46 | $1.76 | $1.87 | - | $1.96 | $1.74 | $2.59 | $1.42 | $1.60 | $1.18 | $1.15 | $1.41 | $2.14 | $1.31 | $1.78 |
| Avg Forecast | $2.53 | $2.58 | $2.68 | $2.67 | $2.44 | $2.45 | $2.52 | $2.52 | $2.39 | $2.48 | $2.53 | $2.45 | $2.28 | $2.22 | $2.20 | $2.37 | $1.88 | $1.94 | $1.93 | $2.00 | $1.64 | $1.55 | $1.61 | $1.76 | $1.36 | $1.41 | $1.62 | $2.23 | $1.54 | $1.76 |
| High Forecast | $2.71 | $2.77 | $2.88 | $2.86 | $2.62 | $2.63 | $2.71 | $2.70 | $2.56 | $2.66 | $2.72 | $2.63 | $2.34 | $2.27 | $2.36 | $2.55 | $2.02 | $2.08 | $1.93 | $2.13 | $1.74 | $1.65 | $1.71 | $1.86 | $1.45 | $1.50 | $1.72 | $2.37 | $1.63 | $1.87 |
| Low Forecast | $2.35 | $2.40 | $2.49 | $2.48 | $2.27 | $2.28 | $2.35 | $2.34 | $2.22 | $2.35 | $2.35 | $2.28 | $2.24 | $2.18 | $2.05 | $2.21 | $1.75 | $1.80 | $1.93 | $1.86 | $1.52 | $1.44 | $1.49 | $1.63 | $1.27 | $1.31 | $1.50 | $2.07 | $1.42 | $1.64 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | 0.93% | 0.97% | 1.04% | 0.94% | 0.96% | - | 0.98% | 1.06% | 1.67% | 0.88% | 0.91% | 0.86% | 0.82% | 0.87% | 0.96% | 0.85% | 1.01% |
According to 4 Wall Street analysts, CME Group's projected average Quarter EPS for Mar 24 is $2.45, with a low estimate of $2.28 and a high estimate of $2.63. This represents a 9.43% increase compared to CME previous annual EPS of $2.24 (Dec 23).
CME Group Peer Comparison by Price Target
CME Forecast FAQ
Is CME Group a good buy?
Yes, according to 13 Wall Street analysts, CME Group (CME) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 46.15% of CME's total ratings.
What is CME's price target?
CME Group (CME) average price target is $213.88 with a range of $151 to $280, implying a -1.43% from its last price of $216.99. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will CME Group stock go up soon?
According to Wall Street analysts' prediction for CME stock, the company can go down by -1.43% (from the last price of $216.99 to the average price target of $213.88), up by 29.04% based on the highest stock price target, and down by -30.41% based on the lowest stock price target.
Can CME Group stock reach $300?
CME's average twelve months analyst stock price target of $213.88 does not support the claim that CME Group can reach $300 in the near future.
What is CME Group's current price target trend?
1 Wall Street analyst forecast a $177 price target for CME Group (CME) this month, down -18.43% from its last price of $216.99. Compared to the last 3 and 12 months, the average price target decreased by -7.37% and decreased by -3.28%, respectively.
What are CME Group's analysts' financial forecasts?
CME Group's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $6.17B (high $6.51B, low $5.83B), average EBITDA is $3.75B (high $3.96B, low $3.54B), average net income is $3.58B (high $3.83B, low $3.32B), average SG&A $198.01M (high $209.04M, low $187.25M), and average EPS is $9.93 (high $10.65, low $9.23). CME's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $6.57B (high $6.93B, low $6.21B), average EBITDA is $3.99B (high $4.21B, low $3.77B), average net income is $3.76B (high $4.04B, low $3.5B), average SG&A $210.8M (high $222.53M, low $199.34M), and average EPS is $10.46 (high $11.22, low $9.72).
Did the CME's actual financial results beat the analysts' financial forecasts?
Based on CME Group's last annual report (Dec 2023), the company's revenue was $5.58B, beating the average analysts forecast of $5.52B by 1.02%. Apple's EBITDA was $3.79B, beating the average prediction of $3.59B by 5.53%. The company's net income was $3.19B, beating the average estimation of $3.15B by 1.05%. Apple's SG&A was $144.4M, missing the average forecast of $296.85M by -51.36%. Lastly, the company's EPS was $8.86, missing the average prediction of $9.08 by -2.43%. In terms of the last quarterly report (Dec 2023), CME Group's revenue was $1.44B, beating the average analysts' forecast of $1.43B by 0.77%. The company's EBITDA was $949.5M, beating the average prediction of $867.83M by 9.41%. CME Group's net income was $804.3M, missing the average estimation of $821.43M by -2.09%. The company's SG&A was $0, missing the average forecast of $45.86M by -100.00%. Lastly, the company's EPS was $2.24, missing the average prediction of $2.28 by -1.87%